Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149

NCT01485874 is registered in ClinicalTrials.gov with Hoosier Cancer Research Network as lead sponsor.

NCT NCT01485874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01485874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149
Lead sponsor
Hoosier Cancer Research Network
Phase
Phase 1
Overall status
Terminated
Start date
November 30, 2011
Completion date
December 31, 2015
Enrollment
11 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer